Article source: Medical Cube Info
On April 18, Clover announced the company's adjuvant protein vaccine SCB-2019 (CpG 1018/aluminum adjuvant) at the 2022 World Vaccine Congress Washington 2022.
More positive data from an ongoing evaluation study derived from an expanded dataset of more than 100 subjects
Clover Bio's new crown vaccine candidate consists of SCB-2019 antigen combined with two adjuvants, namely Dynavax's CpG 1018 adjuvant and aluminum hydroxide (aluminum adjuvant)
The SCB-2019 antigen is a stable trimeric structural fusion protein (S-trimer™) based on the S protein of the original strain of SARS-CoV-2 (new coronavirus)
A new dataset from an extended follow-up analysis confirms earlier findings and shows high and durable protection in individuals approximately 6 months after basal immunization with SCB-2019 (CpG 1018/aluminum adjuvant)
Follow-up analyses involved more than 14,700 subjects with no evidence of exposure to the new coronavirus and more than 14,700 subjects with evidence of previous exposure to the new coronavirus
Durability of protective efficacy for approximately 6 months after primary immunizationDurability of protective efficacy for approximately 6 months after primary immunization
About 6 months after primary immunization, in adults (18-59 years old) without a history of 2019-nCoV infection, the protective efficacy against severe illness remained 100% and the protective efficacy against hospitalization was 95%
In older adults (60 years and older), protection against severe illness remained 100% protective, and protection against hospitalization remained 100%
In individuals previously infected with 2019-nCoV, the protective efficacy against 2019-nCoV of any severity caused by any 2019-nCoV strain was 71% after primary immunization, and no clinical evidence of 2019-nCoV infection was observed over a period of approximately 6 months A trend of decreasing efficacy
After the first dose of SCB-2019 (CpG 1018/aluminum adjuvant) in this population, a rapid increase in neutralizing antibodies was associated with clinical protection against 2019-nCoV, which lasted for about 6 days after basic immunization.
Up-to-date heterologous booster needle data in the extended datasetUp-to-date heterologous booster needle data in the extended dataset
Among individuals previously vaccinated with two doses of AstraZeneca's Covid-19 vaccine, the heterologous booster vaccinated with SCB-2019 (CpG 1018/aluminum adjuvant) induced higher levels of neutralizing antibodies against the prototype strain than those vaccinated with three doses of AstraZeneca vaccine.
Individuals are about 4 times higher
Compared with preliminary data of 76 people announced in February 2022, in the expanded 103 people, vaccination with SCB-2019 (CpG 1018/aluminum adjuvant) heterologous booster strongly activated immune response memory, providing immune maturation.
In individuals previously vaccinated with two doses of AstraZeneca's new crown vaccine, the level of neutralizing antibody induced by the heterologous booster shot with SCB-2019 (CpG 1018/aluminum adjuvant) was higher than that of the three doses of AstraZeneca Individuals with the Likang vaccine were about 3 times higher
Compared with preliminary data published in March 2022 for 79 people, in the expanded 120 people, the SCB-2019 (CpG 1018/aluminum adjuvant) booster shot showed a significant improvement in beta compared with three doses of AstraZeneca vaccine.
, Gamma, Delta, and Omicron were notable variants with stronger neutralizing antibody responses